Theriva Biologics Inc.

AMEX: TOVX · Real-Time Price · USD
0.49
-0.02 (-3.54%)
At close: Jul 24, 2025, 3:59 PM

Theriva Biologics Cash Flow Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Net Income
-25.65M -18.35M -19.68M -14.27M
Depreciation & Amortization
137K 135K 85K 87K
Stock-Based Compensation
671K 552K 475K 416K
Other Working Capital
603K 2.47M -421K 1.24M
Other Non-Cash Items
8.07M -2M 2.27M 952K
Deferred Income Tax
-888K -1.64M -1.43M -952K
Change in Working Capital
726K 2.31M -806K 875K
Operating Cash Flow
-16.94M -19M -19.08M -12.89M
Capital Expenditures
-1K -202K -116K -14K
Cash Acquisitions
n/a n/a -4.28M n/a
Purchase of Investments
n/a n/a -417K n/a
Sales Maturities Of Investments
n/a n/a 421.28K n/a
Other Investing Acitivies
n/a n/a -4.28K n/a
Investing Cash Flow
-1K -202K -4.4M -14K
Debt Repayment
-67K -75K -1.38M n/a
Common Stock Repurchased
n/a n/a -288K n/a
Dividend Paid
n/a n/a n/a n/a
Other Financial Acitivies
n/a -1.52M -3M 8.04M
Financial Cash Flow
5.5M 625K -1.93M 74M
Net Cash Flow
-11.57M -18.61M -25.44M 61.1M
Free Cash Flow
-16.94M -19.2M -19.2M -12.9M